What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Immunology, Internal medicine, Melanoma, Immunotherapy and Talimogene laherparepvec.
His Immunology study combines topics in areas such as Cancer and Vaccinia.
His research integrates issues of Gastroenterology, Surgery and Oncology in his study of Internal medicine.
His work investigates the relationship between Melanoma and topics such as Ipilimumab that intersect with problems in Hydroxychloroquine, Autoimmune disease, Rheumatoid arthritis, Prednisone and CTLA-4.
His biological study deals with issues like ELISPOT, which deal with fields such as ALVAC Vaccine, MART-1 Antigen, CD80 and Tumor microenvironment.
The Talimogene laherparepvec study combines topics in areas such as Granulocyte macrophage colony-stimulating factor and Oncolytic virus.
His most cited work include:
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma (1183 citations)
- Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (674 citations)
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (667 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunotherapy, Internal medicine, Oncology, Immunology and Melanoma.
His Immunotherapy research incorporates themes from Cancer research, Oncolytic virus and Virology.
His study looks at the intersection of Internal medicine and topics like Surgery with Gastroenterology and Adverse effect.
His Overall survival study, which is part of a larger body of work in Oncology, is frequently linked to In patient, bridging the gap between disciplines.
Immunology is closely attributed to Vaccinia in his research.
As part of one scientific family, Howard L. Kaufman deals mainly with the area of Melanoma, narrowing it down to issues related to the Talimogene laherparepvec, and often Unresected and Stage iiib.
He most often published in these fields:
- Immunotherapy (39.94%)
- Internal medicine (39.07%)
- Oncology (33.53%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (39.07%)
- Oncology (33.53%)
- Immunotherapy (39.94%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Immunotherapy, Cancer research and Melanoma.
His Oncology research includes elements of Avelumab, Nivolumab and Surgery.
He is conducting research in Cancer and Immunology as part of his Immunotherapy study.
His Cancer research focuses on Immune system and how it connects with Breast cancer.
His Melanoma study combines topics from a wide range of disciplines, such as Gastroenterology, Talimogene laherparepvec, CD8 and Oncolytic virus.
Howard L. Kaufman interconnects Oncolytic Virus Therapy and Ipilimumab in the investigation of issues within Talimogene laherparepvec.
Between 2016 and 2021, his most popular works were:
- Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (674 citations)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (257 citations)
- Combination immunotherapy: a road map (183 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Immunotherapy, Melanoma, Internal medicine, Cancer and Cancer research.
His research integrates issues of Virus, Oncolytic virus, Tumor Cell Biology and Pandemic in his study of Immunotherapy.
The Oncolytic virus study combines topics in areas such as Targeted therapy, Talimogene laherparepvec and Immunogenicity.
His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology.
In his study, Metastatic melanoma and Clinical study design is strongly linked to Immunology, which falls under the umbrella field of Oncology.
His Cancer study integrates concerns from other disciplines, such as Adverse effect, Clinical trial and Immune system.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
